Document Detail

Antiarrhythmic actions of tocainide in canine models of previous myocardial infarction.
MedLine Citation:
PMID:  1708198     Owner:  NLM     Status:  MEDLINE    
The antiarrhythmic and antifibrillatory efficacies of the class IB antiarrhythmic agent tocainide were characterized in conscious dogs in the early subacute phase of anterior myocardial infarction (48 hours after infarction) and in anesthetized dogs with ventricular tachyarrhythmias that were inducible by programmed stimulation more chronically (10.8 +/- 1.0 days) after anterior myocardial infarction. The frequency of spontaneous premature ventricular complexes in the early subacute postinfarction phase was reduced significantly from 48.4% +/- 10.5% to 8.2% +/- 5.0% of total complexes (p less than 0.01) by the cumulative intravenous administration of 10 mg/kg tocainide. In the late postinfarction setting, the intravenous administration of tocainide (6 mg/kg intravenous loading dose + 100 micrograms/kg/min intravenous maintenance infusion) suppressed the initiation of ventricular tachyarrhythmias by programmed stimulation in 5 of 12 animals that were tested and slowed the rate of tachycardia in 3 additional animals. However, the incidence of ventricular fibrillation and of the total number of arrhythmia-related deaths that resulted from the occurrence of a secondary ischemic insult in the presence of previous infarction did not differ significantly between tocainide (75% [9 of 12] incidence of both ventricular fibrillation and of total number of arrhythmia-related deaths) and saline-vehicle control groups (80% [12 of 15] incidence of ventricular fibrillation; 93.3% [14 of 15] incidence of total number of arrhythmia-related deaths). These findings suggest that although class I agents such as tocainide may be efficacious in the suppression of spontaneous premature ventricular complexes and ventricular arrhythmias immediately after myocardial infarction, they may be of limited value in the prevention of malignant ischemic arrhythmias that occur later after myocardial infarction.
A A Wallace; R F Stupienski; L A Heaney; J R Gehret; J J Lynch
Related Documents :
12065728 - Antiarrhythmic efficacy of combined i(ks) and beta-adrenergic receptor blockade.
22302648 - A new quantification method for mechanical dyssynchrony with three-dimensional echocard...
16442408 - High risk of ventricular arrhythmias in patients with nonischemic dilated cardiomyopath...
10377318 - Stabilisation of medically refractory ventricular arrhythmia by intra-aortic balloon co...
16697308 - Prevention of ventricular desynchronization by permanent para-hisian pacing after atrio...
3578008 - Survival of patients with acute renal failure requiring dialysis after open heart surge...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  121     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  1991 May 
Date Detail:
Created Date:  1991-05-23     Completed Date:  1991-05-23     Revised Date:  2006-02-27    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1413-21     Citation Subset:  AIM; IM    
Department of Pharmacology, Merck, Sharp and Dohme Research Laboratories, West Point, PA 19486.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / therapeutic use*
Cardiac Complexes, Premature / etiology,  prevention & control*
Cardiac Pacing, Artificial
Heart Conduction System / drug effects,  physiopathology
Lidocaine / analogs & derivatives*,  therapeutic use
Myocardial Infarction / complications*
Tachycardia / etiology,  prevention & control*
Time Factors
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 137-58-6/Lidocaine; 41708-72-9/Tocainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Food allergy in children: diagnosis and treatment with sodium cromoglycate.
Next Document:  Sinus parasystole.